Arbutus Biopharma Corp Payments to Acquire Investments
Arbutus Biopharma Corp (ABUS) reported Payments to Acquire Investments of $37.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-12
- Arbutus Biopharma Corp payments to acquire investments for the quarter ending 2026-06-30 was $23.66M, a 16.97% decline year-over-year.
- Arbutus Biopharma Corp payments to acquire investments for the quarter ending 2026-03-31 was $13.80M, a 60.25% decline year-over-year.
- Arbutus Biopharma Corp payments to acquire investments for the quarter ending 2025-12-31 was $25.55M, a 40.85% decline year-over-year.
- Arbutus Biopharma Corp payments to acquire investments for the quarter ending 2025-09-30 was $51.30M, a 27.18% increase year-over-year.
- Arbutus Biopharma Corp payments to acquire investments for fiscal 2025 was $140.06M, a 1.02% decline from fiscal 2024.
- Arbutus Biopharma Corp payments to acquire investments for fiscal 2024 was $141.51M, a 75.77% increase from fiscal 2023.
- Arbutus Biopharma Corp payments to acquire investments for fiscal 2023 was $80.51M, a 38.27% decline from fiscal 2022.
- Arbutus Biopharma Corp payments to acquire investments for fiscal 2022 was $130.43M, a 58.64% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $37.46M 10-Q · filed 2026-08-12 | $63.01M derived: sum of 3 quarters · filed 2026-08-12 | $114.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $13.80M 10-Q · filed 2026-05-13 | $39.35M derived: sum of 2 quarters · filed 2026-05-13 | $90.65M derived: sum of 3 quarters · filed 2026-05-13 | $119.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $25.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $76.85M derived: sum of 2 quarters · filed 2026-03-23 | $105.34M derived: sum of 3 quarters · filed 2026-08-12 | $140.06M 10-K · filed 2026-03-23 |
| 2025-09-30 | $51.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $79.80M derived: sum of 2 quarters · filed 2026-08-12 | $114.51M 10-Q · filed 2025-11-13 | $157.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $28.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $63.21M 10-Q · filed 2026-08-12 | $106.41M derived: sum of 3 quarters · filed 2026-08-12 | $146.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $34.72M 10-Q · filed 2026-05-13 | $77.91M derived: sum of 2 quarters · filed 2026-05-13 | $118.24M derived: sum of 3 quarters · filed 2026-05-13 | $150.83M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $43.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $83.53M derived: sum of 2 quarters · filed 2026-03-23 | $116.11M derived: sum of 3 quarters · filed 2026-03-23 | $141.51M 10-K · filed 2026-03-23 |
| 2024-09-30 | $40.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $72.92M derived: sum of 2 quarters · filed 2025-11-13 | $98.32M 10-Q · filed 2025-11-13 | $122.34M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $32.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $57.98M 10-Q · filed 2025-08-06 | $82.00M derived: sum of 3 quarters · filed 2025-08-06 | $89.09M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $25.40M 10-Q · filed 2025-05-14 | $49.42M derived: sum of 2 quarters · filed 2025-05-14 | $56.50M derived: sum of 3 quarters · filed 2025-05-14 | $85.70M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $24.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $31.10M derived: sum of 2 quarters · filed 2025-03-27 | $60.30M derived: sum of 3 quarters · filed 2025-03-27 | $80.51M 10-K · filed 2025-03-27 |
| 2023-09-30 | $7.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $36.28M derived: sum of 2 quarters · filed 2024-11-06 | $56.49M 10-Q · filed 2024-11-06 | $69.65M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $29.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $49.41M 10-Q · filed 2024-08-08 | $62.57M derived: sum of 3 quarters · filed 2024-08-08 | $95.22M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $20.20M 10-Q · filed 2024-05-02 | $33.37M derived: sum of 2 quarters · filed 2024-05-02 | $66.02M derived: sum of 3 quarters · filed 2024-05-02 | $88.65M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $13.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $45.81M derived: sum of 2 quarters · filed 2024-03-05 | $68.45M derived: sum of 3 quarters · filed 2024-03-05 | $130.43M 10-K · filed 2024-03-05 |
| 2022-09-30 | $32.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $55.28M derived: sum of 2 quarters · filed 2023-11-07 | $117.27M 10-Q · filed 2023-11-07 | $145.33M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $22.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $84.62M 10-Q · filed 2023-08-03 | $112.68M derived: sum of 3 quarters · filed 2023-08-03 | $112.69M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $61.98M 10-Q · filed 2023-05-04 | $90.04M derived: sum of 2 quarters · filed 2023-05-04 | $90.06M derived: sum of 3 quarters · filed 2023-05-04 | $142.17M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $28.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $28.07M derived: sum of 2 quarters · filed 2023-03-02 | $80.19M derived: sum of 3 quarters · filed 2023-03-02 | $82.22M 10-K · filed 2023-03-02 |
| 2021-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $52.13M derived: sum of 2 quarters · filed 2022-11-09 | $54.16M 10-Q · filed 2022-11-09 | $110.83M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $52.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $54.15M 10-Q · filed 2022-08-04 | $110.82M derived: sum of 3 quarters · filed 2022-08-04 | $113.81M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.03M 10-Q · filed 2022-05-05 | $58.70M derived: sum of 2 quarters · filed 2022-05-05 | $61.70M derived: sum of 3 quarters · filed 2022-05-05 | $63.24M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $56.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $59.67M derived: sum of 2 quarters · filed 2022-03-03 | $61.21M derived: sum of 3 quarters · filed 2022-03-03 | $85.58M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.54M derived: sum of 2 quarters · filed 2021-11-04 | $28.90M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $25.91M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $24.37M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $58.76M 10-K · filed 2021-03-04 | |||
| 2019-06-30 | $484.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $121.58M 10-K · filed 2020-03-05 | |||
| 2014-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$1.01M derived: sum of 2 quarters · filed 2015-03-13 | $41.98M derived: sum of 3 quarters · filed 2015-03-13 | $41.98M 10-K · filed 2015-03-13 |
| 2014-09-30 | $291.00K 10-Q · filed 2014-11-07 | $43.28M derived: sum of 2 quarters · filed 2014-11-07 | $43.28M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $42.99M 10-Q · filed 2014-08-14 | $42.99M 10-Q · filed 2014-08-14 | ||
| 2014-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |